

Special Issue

Recent Updates and Future Perspectives on Anti-Cancer Agents

Message from the Guest Editor

Cancer is a complex and challenging disease that imposes a significant economic burden on society. Despite extensive research aimed at understanding its biology, cancer remains persistent, and there is no cure for its advanced stages. As a result, there is growing interest within the scientific community in developing anti-cancer agents. This Special Issue will focus on the key challenges and recent advancements in targeted therapeutics that aim to improve effectiveness, reduce side effects, and overcome mechanisms of drug resistance in cancer treatment. We invite authors to submit their research and review articles on the latest progress in therapeutic agents for this Special issue, entitled "Recent Updates and Future Perspectives of Anti-Cancer Agents". We will consider articles focusing on anti-cancer drugs, natural compounds, combination therapy, targeted therapy, nanotherapy, and translational therapy. The ultimate goal is to enhance our understanding of cancer and develop promising therapies that will improve patients' overall quality of life. I look forward to receiving your contributions.

Guest Editor

Dr. Santosh Kumar Singh

Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA

Deadline for manuscript submissions

15 August 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/224929

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)